Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of S-217622 for SARS-CoV-2 infection
jRCT2031210350Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing S-217622 with Placebo (2 arms). Primary endpoints: Change from baseline in SARS-CoV-2 viral titer at each time point, Time-weighted average change in total score of 12 COVID-19 symptoms from Day 1 up to Day 6 and 4 more. Started Sep 2021; status: completed.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210350.